| 陈 颖,李薛梅,李 靖,王秋棠,蓝晓红,马晓华.基于PI3K/AKT/mTOR信号通路探讨芪苈强心胶囊联合瑞舒伐他汀治疗冠心病的疗效及其作用机制[J].,2024,(19):3645-3647 |
| 基于PI3K/AKT/mTOR信号通路探讨芪苈强心胶囊联合瑞舒伐他汀治疗冠心病的疗效及其作用机制 |
| Investigate the Efficacy and Mechanism of Qiliqiangxin Capsule Combined with Rosuvastatin in the Treatment of Coronary Heart Disease Based on PI3K/AKT/mTOR Signaling Pathway |
| 投稿时间：2024-04-25 修订日期：2024-05-21 |
| DOI：10.13241/j.cnki.pmb.2024.19.009 |
| 中文关键词: PI3K/AKT/mTOR信号通路 芪苈强心胶囊 瑞舒伐他汀 冠心病 |
| 英文关键词: PI3K/AKT/mTOR signaling pathway Qili Qiangxin capsule Rosuvastatin Coronary heart disease |
| 基金项目:江苏省医院药学基金项目（H202003） |
|
| 摘要点击次数: 24 |
| 全文下载次数: 11 |
| 中文摘要: |
| 摘要 目的：基于磷脂酰肌醇3激酶（PI3K）/蛋白激酶B（AKT）/哺乳动物雷帕霉素靶蛋白（mTOR）信号通路探讨芪苈强心胶囊联合瑞舒伐他汀治疗冠心病的疗效及其作用机制。方法：采用信封抽签法将113例冠心病患者分为对照组(n=56)和研究组(n=57)。对照组在常规治疗的基础上接受瑞舒伐他汀治疗，研究组在对照组基础上联合芪苈强心胶囊治疗。对比两组疗效、血管内皮功能、炎症因子、氧化应激指标、PI3K/AKT/mTOR信号通路相关指标以及不良反应发生率。结果：研究组的临床总有效率高于对照组（P<0.05）。研究组治疗后白细胞介素-6（IL-6）、PI3K信使核糖核酸（mRNA）、内皮素-1（ET-1）、AKT mRNA、肿瘤坏死因子-α（TNF-α）、单核细胞趋化蛋白-1（MCP-1）、mTOR mRNA、丙二醛（MDA）低于对照组，一氧化氮（NO）、超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）高于对照组（P<0.05）。两组不良反应总发生率无差异（P>0.05）。结论：芪苈强心胶囊联合瑞舒伐他汀治疗冠心病的疗效确切，可改善患者血管内皮功能，抑制炎症反应和氧化应激，其作用机制可能与调控PI3K/AKT/mTOR信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy and mechanism of Qili Qiangxin capsule combined with rosuvastatin in the treatment of coronary heart disease based on phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway. Methods: 113 patients with coronary heart disease were divided into control group (n=56) and study group (n=57) by envelope drawing method. The control group was treated with rosuvastatin on the basis of routine treatment, and the study group was treated with Qili Qiangxin capsule on the basis of the control group. The efficacy, vascular endothelial function, inflammatory factors, oxidative stress indexes, PI3K/AKT/mTOR signaling pathway related indexes and incidence of adverse reactions were compared between two groups. Results: The total clinical effective rate in study group was higher than that in control group (P<0.05). The levels of interleukin-6 (IL-6), PI3K messenger ribonucleic acid (mRNA), endothelin-1 (ET-1), AKT mRNA, tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), mTOR mRNA, malondialdehyde (MDA)in study group were lower than those in the control group, and nitric oxide (NO), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were higher than those in control group after treatment (P<0.05). There was no difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion: Qili Qiangxin capsule combined with rosuvastatin is effective in the treatment of coronary heart disease, which can improve vascular endothelial function, inhibit inflammatory response and oxidative stress, its mechanism may be related to the regulation of PI3K/AKT/mTOR signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
